A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLN0128 (an Oral mTORC 1/2 Inhibitor) as a Single Agent and in Combination With Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
At a glance
- Drugs Sapanisertib (Primary) ; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology
- 30 Jan 2018 Planned end date changed from 31 Oct 2017 to 30 Apr 2018.
- 18 Apr 2017 Planned End Date changed from 1 Apr 2017 to 31 Oct 2017.
- 11 Jan 2017 Planned End Date changed from 1 Jan 2016 to 1 Apr 2017.